SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 1, 2003

Beckman Coulter, Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-10109	95-104-0600
(State of	(Commission File Number)	(IRS Employer
Incorporation)		Identification No.)

4300 N. Harbor Boulevard
Fullerton, California 92834-3100
(Address of principal executive offices) (Zip Code)

(714) 871-4848
(Registrant’s telephone number, including area code)

Item 7. Exhibits

Exhibit 99.1 Press Release “Beckman Coulter Settles Claim Against 1997 Acquisition Escrow Account”

Item 9. Regulation FD Disclosure

On April 1, 2003, Beckman Coulter, Inc. issued the press release attached as Exhibit 99.1.

EXHIBIT INDEX

Exhibits

Exhibit 99.1 Press Release “Beckman Coulter Settles Claim Against 1997 Acquisition Escrow Account”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 1, 2003

BECKMAN COULTER, INC.

	By:	/s/ William H. May
	Name: William H. May
	Title: Vice President, General Counsel, and
	Secretary

FULLERTON, California, April 1, 2003 - Beckman Coulter, Inc. (NYSE:BEC) announced today that in the first quarter of 2003, it will record a $28.9 million non-taxable credit to operating income associated with the settlement of its claims against an escrow account. The company will also record a tax deductible charge of approximately $2.0 million for additional legal fees related to its escrow claim and the escrow settlement. The escrow account was created as part of the Beckman Instruments, Inc. 1997 acquisition of Coulter Corporation to cover contingent pre-acquisition liabilities. After taxes, the $27.7 million credit covers all of Beckman Coulter’s claims against the escrow account, including the charges taken in the fourth quarter of 2002.

Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2.06 billion in 2002, with 62% of this amount generated by recurring revenue from supplies, test kits and services. For more information, visit www.beckmancoulter.com.

###

Contact:		Jeanie Herbert		(714) 773-7620
		Director, Investor Relations